Andreas Haldemann

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Christian Waldherr, Miklos Pless, Helmut R. Maëcke et al. · PubMed · 2002 · 446 citations

Medicine, Oncology, Pharmacology +15

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

Christian Waldherr, Misha Pless, Helmut R. Maëcke et al. · Annals of Oncology · 2001 · 394 citations

Medicine, Nuclear Medicine, Oncology +11

Poorly Differentiated Thyroid Carcinomas

Matthias S. Dettmer, Anja Schmitt, Hans C. Steinert et al. · The American Journal of Surgical Pathology · 2011 · 72 citations

Medicine, Oncology, Pathology +16

Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.

Andreas Haldemann, Helmuth Rösler, Alain Barth et al. · PubMed · 1995 · 72 citations

Medicine, Nuclear Medicine, Oncology +17

Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: a pilot study

Christian Waldherr, Tilmann Schumacher, Miklos Pless et al. · Nuclear Medicine Communications · 2001 · 71 citations

Medicine, Nuclear Medicine, Oncology +17